Medical articles using miscible composition

Abstract

Provided is a medical article with improved moisture vapor transmission rate of the pressure sensitive adhesive layer with a miscible composition. The medical article has a backing, a pressure sensitive adhesive layer with acid-functional groups or basic-functional groups, an MVTR-modifying composition that is basic when the PSA comprises an acidic-functional group or is acidic when the PSA comprises a basic-functional group, and a filtration layer disposed between the MVTR-modifying layer and the PSA layer. The MVTR-modifying composition is miscible with the PSA, and contact between the MVTR-modifying composition and the PSA causes an acid-base reaction to form a poly-salt and increase moisture permeability of at least a portion of the PSA layer.

What is claimed is: 
     
         1 . A medical article comprising:
 a backing having a first major surface and a second major surface;   a PSA layer disposed on at least a portion of the first major surface of the backing, wherein the PSA layer comprises a PSA comprising acid-functional groups or basic-functional groups;   an MVTR-modifying layer comprising an MVTR-modifying composition that is basic when the PSA comprises an acidic-functional group or is acidic when the PSA comprises a basic-functional group; and   a filtration layer disposed between the MVTR-modifying layer and the PSA layer;   wherein the MVTR-modifying composition is miscible with the PSA, and contact between the MVTR-modifying composition and the PSA causes an acid-base reaction to form a poly-salt and increase moisture permeability of at least a portion of the PSA layer.   
     
     
         2 . The medical article of  claim 1  further comprising ionic groups non-uniformly distributed throughout the PSA layer, wherein the ionic groups are formed from a reaction of the PSA functional groups and the MVTR-modifying composition. 
     
     
         3 . The medical article of  claim 1 , wherein the MVTR-composition further comprises a plasticizer. 
     
     
         4 . The medical article of  claim 1 , wherein the PSA includes at least 0.84 mmoles acidic- or basic-functional groups per gram PSA. 
     
     
         5 . The medical article of  claim 1 , wherein the MVTR-modifying composition comprises an inorganic acid or an inorganic base. 
     
     
         6 . The medical article of  claim 1 , wherein the MVTR-modifying composition comprises an organic acid or an organic base. 
     
     
         7 . The medical article of  claim 1 , wherein the MVTR-modifying layer further comprises a scaffold. 
     
     
         8 . The medical article of  claim 7 , wherein the scaffold is coated with the MVTR-modifying composition. 
     
     
         9 . The medical article of  claim 1 , wherein the PSA layer comprises a (meth)acrylate polymer, and wherein said polymer is prepared from at least 6 wt-% acidic- or basic-functional monomers, based on total weight of the PSA. 
     
     
         10 . The medical article of  claim 1 , wherein the PSA layer comprises a polymer having acid-functional groups, and the MVTR-modifying composition is basic. 
     
     
         11 . The medical article of  claim 10 , wherein the MVTR-modifying composition comprises a base selected from a group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, silver hydroxide, zinc hydroxide, ammonium hydroxide, magnesium hydroxide, barium hydroxide, strontium hydroxide, cesium hydroxide, rubidium hydroxide, ammonium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, silver carbonate, lithium carbonate, lithium bicarbonate, barium bicarbonate, magnesium carbonate, cesium carbonate, triethanolamine, methyldiethanolamine, pyridine, benzimidizole, histidine, triethylamine, monoethanolamine, diethanolamine, hydrates thereof, and combinations thereof. 
     
     
         12 . The medical article of  claim 1 , wherein the PSA layer comprises a polymer having basic functional groups, and the MVTR-modifying composition is acidic. 
     
     
         13 . The medical article of  claim 12 , wherein the MVTR-modifying composition comprises an acid selected from a group consisting of formic acid, acetic acid, lactic acid, sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, or combinations thereof. 
     
     
         14 . The medical article of  claim 1 , which has a wet MVTR of at least 1200 g/m 2 /24 hours. 
     
     
         15 . The medical article of  claim 1 , wherein the filtration layer is a pH-altering layer. 
     
     
         16 . The medical article of  claim 1 , wherein the filtration layer comprises a nonwoven, woven, gel, or foam. 
     
     
         17 . The medical article of  claim 16 , wherein the filtration layer comprises a nonwoven. 
     
     
         18 . The medical article of  claim 1 , which is a wound dressing. 
     
     
         19 . A medical article comprising:
 a backing having a first major surface and a second major surface;   a PSA layer disposed on at least a portion of the first major surface of the backing, wherein the PSA layer comprises a PSA comprising acid-functional groups or basic-functional groups;   an MVTR-modifying layer comprising an MVTR-modifying composition that is basic when the PSA comprises an acidic-functional group or is acidic when the PSA comprises a basic-functional group, wherein the MVTR-modifying composition is miscible with the PSA;   a filtration layer disposed between the MVTR-modifying layer and the PSA layer; and   ionic groups non-uniformly distributed throughout the PSA layer, wherein the ionic groups are formed from a reaction of the PSA functional groups and the MVTR-modifying composition.   
     
     
         20 . The medical article of  claim 19 , wherein the filtration layer comprises a nonwoven.